Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents

다국어 초록 (Multilingual Abstract)

Omega-3 polyunsaturated fatty acids (or omega-3 PUFAs, n-3 PUFAs) are essential nutrients throughout the life span.
Recent studies have shown the importance of n-3 PUFAs supplementation during prenatal and perinatal period as a potential protective factor of neurodevelopmental disorders. N-3 PUFAs have been reported to be lower in youth with attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and major depressive disorder (MDD).
N-3 PUFAs supplementation has shown potential effects in the improvement of clinical symptoms in youth with ADHD, ASD, and MDD, especially those with high inflammation or a low baseline n-3 index. Moreover, it has been suggested that n-3 PUFAs had positive effects on lethargy and hyperactivity symptoms in ASD. For clinical application, the following dosage and duration are recommended in youth according to available randomized controlled trials and systemic literature review: (1) ADHD: a combination of eicosapentaenoic acid (EPA) ＋ docosahexaenoic acid (DHA) ≥ 750 mg/d, and a higher dose of EPA (1,200 mg/d) for those with inflammation or allergic diseases for duration of 16−24 weeks; (2) MDD: a combination of a EPA ＋ DHA of 1,000−2,000 mg/d, with EPA:DHA ratio of 2 to 1, for 12−16 weeks; (3) ASD: a combination of EPA ＋ DHA of 1,300−1,500 mg/d for 16−24 weeks as add-on therapy to target lethargy and hyperactivity symptoms. The current review also suggested that n-3 index and inflammation may be potential treatment response markers for youth, especially in ADHD and MDD, receiving n-3 PUFA.

참고문헌 (Reference)

• 1 Horvath A, "ω-3 fatty acid supplementation does not affect autism spectrum disorder in children:a systematic review and meta-analysis" 147 : 367-376, 2017
• 2 Pryweller JR, "White matter correlates of sensory processing in autism spectrum disorders" 6 : 379-387, 2014
• 3 Puri BK, "Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials" 90 : 179-189, 2014
• 4 Kelly JR, "Transferring the blues : depression-associated gut microbiota induces neurobehavioural changes in the rat" 82 : 109-118, 2016
• 5 Adams JB, "The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels" 2009 : 532640-, 2009
• 6 Carver JD, "The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects" 56 : 79-85, 2001
• 7 Chang JP, "The lipid raft hypothesis : the relation among omega-3 fatty acids, depression and cardiovascular diseases" 24 : 168-180, 2010
• 8 Véricel E, "The influence of low intake of n-3 fatty acids on platelets in elderly people" 147 : 187-192, 1999
• 9 Agostoni C, "The first model of keeping energy balance and optimal psycho affective development : breastfed infants" 224 : 10-15, 2017
• 10 Nishi D, "The efficacy of omega-3 fatty acids for depressive symptoms among pregnant women in Japan and Taiwan : a randomized, double-blind, placebo-controlled trial(SYNCHRO; NCT01948596)" 88 : 122-124, 2019
• 11 Chiu CC, "The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment : a preliminary randomized double-blind placebo-controlled study" 32 : 1538-1544, 2008
• 12 Manor I, "The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children : a double-blind placebo-controlled trial, followed by an open-label extension" 27 : 335-342, 2012
• 13 Lauritzen L, "The effect of fish oil supplementation on heart rate in healthy Danish infants" 64 : 610-614, 2008
• 14 March JS, "The Treatment for Adolescents with Depression Study(TADS) : long-term effectiveness and safety outcomes" 64 : 1132-1143, 2007
• 15 Higgins S, "Susceptibility of LDL to oxidative modification in healthy volunteers supplemented with low doses of n-3 polyunsaturated fatty acids" 85 : 23-31, 2001
• 16 Higdon JV, "Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate" 42 : 407-418, 2001
• 17 Cheng YS, "Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders : a meta-analysis of randomized controlled trials" 13 : 2531-2543, 2017
• 18 Matsuo N, "Studies on the toxicity of fish oil. V. Toxicity of oxidized commercial cod-liver oil" 8 : 96-100, 1961
• 19 van de Wouw M, "Short-chain fatty acids : microbial metabolites that alleviate stress-induced brain-gut axis alterations" 596 : 4923-4944, 2018
• 20 Chang CH, "Safety and tolerability of prescription omega-3 fatty acids : a systematic review and meta-analysis of randomized controlled trials" 129 : 1-12, 2018
• 21 Mazahery H, "Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder : systematic review and meta-analysis of case-control and randomised controlled trials" 9 : 155-, 2017
• 22 Rojas DC, "Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms" 6 : 56-, 2006
• 23 Raine A, "Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years : a randomized, double-blind, placebo-controlled, stratified, parallel-group trial" 56 : 509-520, 2015
• 24 Rhee SH, "Principles and clinical implications of the brain-gut-enteric microbiota axis" 6 : 306-314, 2009
• 25 Chang JP, "Polyunsaturated fatty acids(PUFAs)levels in patients with cardiovascular diseases(CVDs)with and without depression" 44 : 28-31, 2015
• 26 Chang JP, "Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy" 80 (80): 273-278, 2018
• 27 Gillies D, "Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents" 2012 : CD007986-, 2012
• 28 Nishi D, "Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women" 85 : 29-34, 2020
• 29 Farooqui AA, "Phospholipase A2-generated lipid mediators in the brain : the good, the bad, and the ugly" 12 : 245-260, 2006
• 30 Su KP, "Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels" 67 : 550-557, 2010
• 31 Ghezzo A, "Oxidative stress and erythrocyte membrane alterations in children with autism : correlation with clinical features" 8 : e66418-, 2013
• 32 Mohan IK, "Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus" 56 : 193-198, 1997
• 33 Bradberry JC, "Overview of omega-3 fatty acid therapies" 38 : 681-691, 2013
• 34 Robson LG, "Omega-3polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals" 31 : 678-687, 2010
• 35 Cooper RE, "Omega-3polyunsaturated fatty acid supplementation and cognition : a systematic review and meta-analysis" 29 : 753-763, 2015
• 36 Nemets H, "Omega-3 treatment of childhood depression : a controlled, double-blind pilot study" 163 : 1098-1100, 2006
• 37 Zhang R, "Omega-3 polyunsaturated fatty acids inhibit the increase in cytokines and chemotactic factors induced in vitro by lymph fluid from an intestinal ischemia-reperfusion injury model" 31 : 508-514, 2015
• 38 Chang JP, "Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder : a systematic review and meta-analysis of clinical trials and biological studies" 43 : 534-545, 2018
• 39 Chang JP, "Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder-results from a randomized controlled trial" 85 : 14-20, 2020
• 40 Christensen JH, "Omega-3 polyunsaturated fatty acids and heart rate variability" 2 : 84-, 2011
• 41 Siscovick DS, "Omega-3 polyunsaturated fatty acid(fish oil)supplementation and the prevention of clinical cardiovascular disease : a science advisory from the American Heart Association" 135 : e867-e884, 2017
• 42 Amminger GP, "Omega-3 fatty acids supplementation in children with autism : a double-blind randomized, placebo-controlled pilot study" 61 : 551-553, 2007
• 43 Su KP, "Omega-3 fatty acids in the prevention of interferon-alphainduced depression : results from a randomized, controlled trial" 76 : 559-566, 2014
• 44 Ooi YP, "Omega-3 fatty acids in the management of autism spectrum disorders : findings from an open-label pilot study in Singapore" 69 : 969-971, 2015
• 45 Su KP, "Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial" 13 : 267-271, 2003
• 46 Su KP, "Omega-3 fatty acids for major depressive disorder during pregnancy : results from a randomized, double-blind, placebo-controlled trial" 69 : 644-651, 2008
• 47 Chiu CC, "Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder" 66 : 1613-1614, 2005
• 48 Chalon S, "Omega-3 fatty acids and monoamine neurotransmission" 75 : 259-269, 2006
• 49 Bloch MH, "Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology : systematic review and meta-analysis" 50 : 991-1000, 2011
• 50 Nishi D, "Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan : An open-label trial" 70 : 253-254, 2016
• 51 Hibbeln JR, "Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation : opportunities for intervention" 18 : 107-118, 2006
• 52 Hawkey E, "Omega-3 fatty acid and ADHD : blood level analysis and meta-analytic extension of supplementation trials" 34 : 496-505, 2014
• 53 Innis SM, "Omega-3 Fatty acids and neural development to 2years of age: do we know enough for dietary recommendations?" 48 (48): S16-S24, 2009
• 54 Stoll AL, "Omega 3 fatty acids in bipolar disorder : a preliminary double-blind, placebo-controlled trial" 56 : 407-412, 1999
• 55 Meiri G, "Omega 3 fatty acid treatment in autism" 19 : 449-451, 2009
• 56 Sonuga-Barke EJ, "Nonpharmacological interventions for ADHD : systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments" 170 : 275-289, 2013
• 57 Palozza P, "N-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation" 64 : 297-304, 1996
• 58 Chang JP, "More fish-happier mom, smarter child?" 73 : 157-158, 2018
• 59 Frank DN, "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases" 104 : 13780-13785, 2007
• 60 Vloet TD, "Mean heart rate and parameters of heart rate variability in depressive children and the effects of antidepressant medication" 47 : 253-260, 2019
• 61 Hibbeln JR, "Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood(ALSPAC study) : an observational cohort study" 369 : 578-585, 2007
• 62 Calviello G, "Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues" 32 : 1075-1083, 1997
• 63 El-Ansary A, "Lipid mediators in plasma of autism spectrum disorders" 11 : 160-, 2012
• 64 Katan MB, "Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue : an 18-month controlled study" 38 : 2012-2022, 1997
• 65 Guu TW, "International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder" 88 : 263-273, 2019
• 66 Wander RC, "Influence of long-chain polyunsaturated fatty acids on oxidation of low density lipoprotein" 59 : 143-151, 1998
• 67 Rapaport MH, "Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder : a proof-of-concept study" 21 : 71-79, 2016
• 68 Grundt H, "Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids(PUFAs)following an acute myocardial infarction" 57 : 793-800, 2003
• 69 Browning LM, "Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish" 96 : 748-758, 2012
• 70 Connor WE, "Importance of n-3 fatty acids in health and disease" 71 (71): 171S-175S, 2000
• 71 Al-Farsi YM, "Impact of nutrition on serum levels of docosahexaenoic acid among Omani children with autism" 29 : 1142-1146, 2013
• 72 Marchezan J, "Immunological dysfunction in autism spectrum disorder : a potential target for therapy" 25 : 300-319, 2018
• 73 Chang JP, "High-dose eicosapentaenoic acid(EPA)improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder(ADHD)and low endogenous EPA levels" 9 : 303-, 2019
• 74 Paniccia M, "Heart rate variability in healthy non-concussed youth athletes : exploring the effect of age, sex, and concussion-like symptoms" 8 : 753-, 2018
• 75 Hibbeln JR, "Healthy intakes of n-3 and n-6 fatty acids : estimations considering worldwide diversity" 83 (83): 1483S-1493S, 2006
• 76 Trompette A, "Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis" 20 : 159-166, 2014
• 77 Zheng P, "Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism" 21 : 786-796, 2016
• 78 Shimamoto C, "Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies" 23 : 6495-6511, 2014
• 79 Turley E, "Fish oil supplementation with and without added vitamin E differentially modulates plasma antioxidant concentrations in healthy women" 33 : 1163-1167, 1998
• 80 Colter AL, "Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents : a case-control study" 7 : 8-, 2008
• 81 Chouinard-Watkins R, "Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease?" 6 : 4452-4471, 2014
• 82 Harris WS, "Expert opinion: omega-3 fatty acids and bleeding-cause for concern?" 99 : 44C-46C, 2007
• 83 Biederman J, "Evidence of familial association between attention deficit disorder and major affective disorders" 48 : 633-642, 1991
• 84 Rossignol DA, "Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism" 5 : 150-, 2014
• 85 Abdelmagid SA, "Ethnicity, sex, FADS genetic variation, and hormonal contraceptive use influence delta-5- and delta-6-desaturase indices and plasma docosahexaenoic acid concentration in young Canadian adults: a cross-sectional study" 12 : 14-, 2015
• 86 Das UN, "Essential fatty acids : biochemistry, physiology and pathology" 1 : 420-439, 2006
• 87 Stevens LJ, "Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder" 62 : 761-768, 1995
• 88 Trebatická J, "Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents : a pilot study" 11 : 30-, 2017
• 89 Zhao Y, "Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation" 23 : 71-78, 2004
• 90 Halvorsen B, "Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil and butter on the susceptibility of low density lipoprotein to oxidative modification in men" 50 : 364-370, 1996
• 91 Farjadian S, "Effects of omega-3 fatty acids on serum levels of T-helper cytokines in children with asthma" 85 : 61-66, 2016
• 92 Jain S, "Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study" 50 : 1028-1033, 2002
• 93 Cao D, "Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures" 16 : 538-546, 2005
• 94 Widenhorn-Müller K, "Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit/hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial" 91 : 49-60, 2014
• 95 Mori TA, "Effect of omega 3 fatty acids on oxidative stress in humans : GC-MS measurement of urinary F2-isoprostane excretion" 5 : 45-46, 2000
• 96 Parinyasiri U, "Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy" 87 : 143-149, 2004
• 97 Ramírez-Tortosa MC, "Effect of extra-virgin olive oil and fish-oil supplementation on plasma lipids and susceptibility of lowdensity lipoprotein to oxidative alteration in free-living Spanish male patients with peripheral vascular disease" 18 : 167-174, 1999
• 98 Rhodes LE, "Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVRrelated cancer risk in humans. An assessment of early genotoxic markers" 24 : 919-925, 2003
• 99 Mori TA, "Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects" 35 : 772-781, 2003
• 100 Torpy JM, "Eating fish : health benefits and risks" 296 : 1926-, 2006
• 101 Pivik RT, "Early infant diet and the omega 3 fatty acid DHA : effects on resting cardiovascular activity and behavioral development during the first half-year of life" 34 : 139-158, 2009
• 102 Stevens L, "EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors" 38 : 1007-1021, 2003
• 103 Stonehouse W, "Does consumption of LC omega-3 PUFA enhance cognitive performance in healthy school-aged children and throughout adulthood? Evidence from clinical trials" 6 : 2730-2758, 2014
• 104 Calderon F, "Docosahexaenoic acid promotes neurite growth in hippocampal neurons" 90 : 979-988, 2004
• 105 Yavin E, "Docosahexaenoic acid accumulation in the prenatal brain : prooxidant and antioxidant features" 16 : 229-235, 2001
• 106 Wu A, "Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats" 21 : 1457-1467, 2004
• 107 Labrousse VF, "Dietary omega-3 deficiency exacerbates inflammation and reveals spatial memory deficits in mice exposed to lipopolysaccharide during gestation" 73 : 427-440, 2018
• 108 Abel S, "Dietary modulation of fatty acid profiles and oxidative status of rat hepatocyte nodules : effect of different n-6/n-3 fatty acid ratios" 39 : 963-976, 2004
• 109 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" American Psychiatric Association 2013
• 110 McNamara RK, "Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder" 2 : 38-46, 2014
• 111 Chang JP, "Delay aversion, temporal processing, and n-3 fatty acids intake in children with attention-deficit/hyperactivity disorder(ADHD)" 4 : 1094-1103, 2016
• 112 Napoli E, "Deficits in bioenergetics and impaired immune response in granulocytes from children with autism" 133 : e1405-e1410, 2014
• 113 Barbosa DS, "Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids" 19 : 837-842, 2003
• 114 Lauritzen L, "DHA effects in brain development and function" 8 : 6-, 2016
• 115 Vaisman N, "Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention : effect of dietary n-3fatty acids containing phospholipids" 87 : 1170-1180, 2008
• 116 Biederman J, "Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders" 148 : 564-577, 1991
• 117 Ganesh BP, "Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice" 8 : e74963-, 2013
• 118 Perera H, "Combined 3 and 6 supplementation in children with attention-deficit hyperactivity disorder(ADHD)refractory to methylphenidate treatment : a double-blind, placebo-controlled study" 27 : 747-753, 2012
• 119 Sinn N, "Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms : a randomised controlled trial" 78 : 311-326, 2008
• 120 Volkow ND, "Clinical practice : adult attention deficit-hyperactivity disorder" 369 : 1935-1944, 2013
• 121 Bourassa MW, "Butyrate, neuroepigenetics and the gut microbiome : can a high fiber diet improve brain health" 625 : 56-63, 2016
• 122 Bryn V, "Brain derived neurotrophic factor(BDNF)and autism spectrum disorders(ASD)in childhood" 19 : 411-414, 2015
• 123 Wheaton DH, "Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa" 121 : 1269-1278, 2003
• 124 Su KP, "Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a ‘mind-body interface’?" 17 : 144-152, 2009
• 125 Chang JP, "BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients" 136 : 111-115, 2018
• 126 Sgoifo A, "Autonomic dysfunction and heart rate variability in depression" 18 : 343-352, 2015
• 127 Brigandi SA, "Autistic children exhibit decreased levels of essential Fatty acids in red blood cells" 16 : 10061-10076, 2015
• 128 Childress AC, "Attention-deficit/hyperactivity disorder with inadequate response to stimulants : approaches to management" 28 : 121-129, 2014
• 129 Biederman J, "Attention-deficit hyperactivity disorder" 366 : 237-248, 2005
• 130 Brookes KJ, "Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder" 60 : 1053-1061, 2006
• 131 Su KP, "Are omega3 fatty acids beneficial in depression but not mania?" 57 : 716-717, 2000
• 132 Lin PY, "Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression" 17 : 1161-1163, 2012
• 133 Linseisen J, "Antioxidant status of surgical patients receiving TPN with an omega-3-fatty acid-containing lipid emulsion supplemented with alpha-tocopherol" 19 : 177-184, 2000
• 134 Guida F, "Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice" 67 : 230-245, 2018
• 135 Tedelind S, "Anti-inflammatory properties of the short-chain fatty acids acetate and propionate : a study with relevance to inflammatory bowel disease" 13 : 2826-2832, 2007
• 136 M SalLam, "Anti-inflammatory effect of Omega-3 polyunsaturated fatty acids in children with bronchial asthma; relation to nuclear factor-kappa B (NF-κB) and inflammatory cytokines il-12 and il-13" African Journals Online (AJOL) 28 (28): 2010
• 137 Jiang H, "Altered fecal microbiota composition in patients with major depressive disorder" 48 : 186-194, 2015
• 138 Wilens TE, "Alcohol, drugs, and attention-deficit/hyperactivity disorder : a model for the study of addictions in youth" 20 : 580-588, 2006
• 139 Tholstrup T, "A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men" 134 : 1051-1057, 2004
• 140 Mankad D, "A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism" 6 : 18-, 2015
• 141 Voigt RG, "A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder" 139 : 189-196, 2001
• 142 Richardson AJ, "A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties" 26 : 233-239, 2002
• 143 Watson H, "A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota" 67 : 1974-1983, 2018
• 144 Lin PY, "A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3fatty acids" 68 : 1056-1061, 2007
• 145 Gabbay V, "A double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression" 79 : 17-, 2018
• 146 Peet M, "A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs" 59 : 913-919, 2002